Logo

Alexandre Mérieux

Dec 15, 2017

Alexandre Mérieux has been appointed chairman and CEO of BioMérieux's board, effective immediately. He has served as deputy CEO of the company for the past three years and succeeds Jean-Luc Bélingard, who had been chairman and CEO of BioMérieux since 2010. Mérieux will remain as a director of the company and will continue as vice president of Institut Mérieux. 

Mérieux was corporate vice president of BioMérieux's microbiology unit between 2011 and 2014, after directing the industry unit from 2005 to 2011. He is currently chairman of Mérieux Développement and chairs the board of Mérieux NutriSciences.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.